A Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone Deficiency

NCT03075644 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

62

Enrollment

INDUSTRY

Sponsor class

Conditions

Growth Hormone Disorder
Adult Growth Hormone Deficiency

Interventions

DRUG: somapacitan
DRUG: Norditropin

Sponsor

Novo Nordisk A/S